Article

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial

2021-01-11

Abstract excerpt

Dolutegravir, a second-generation integrase strand transfer inhibitor (InSTI), is replacing efavirenz as first-line antiretroviral therapy (ART) in low middle-income countries (LMICs). Tuberculosis remains the leading cause of HIV-related morbidity and mortality in LMICs. Rifampicin is a key agent in the treatment of tuberculosis but induces genes involved in dolutegravir metabolism and efflux. The resulting drug-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 08688e7d-1f72-5fef-9d28-c793e74fb46c
DOI: 10.12688/wellcomeopenres.16473.1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trialDOI 10.12688/wellcomeopenres.16473.1Read

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trialSemantic proximity Read

Bedaquiline, pretomanid and linezolid in multidrug-resistant and pre-extensively drug-resistant tuberculosis in refugees from Ukraine and Somalia in GermanySemantic proximity Read

Protocol for a phase 2, partially-blinded, randomised trial assessing the safety and efficacy of sorfequiline or bedaquiline, in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009)Semantic proximity Read

The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis.Semantic proximity Read

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.Semantic proximity Read

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.Semantic proximity Read

HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol.Semantic proximity Read

Dolutegravir plus lamivudine for the treatment of HIV-1 infection.Semantic proximity Read

Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.Semantic proximity Read

Determinants of HIV-1 virologic suppression in HIV-associated tuberculosis in Brazil.Semantic proximity Read

Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis.Semantic proximity Read

Empiric tuberculosis treatment and 12-month mortality among sputum GeneXpert-negative adults living with HIV in Uganda in the era of widespread Antiretroviral therapy: A prospective cohort studySemantic proximity Read